Commenting on the announcement, Aisling Burnand, Chief Executive of AMRC said:
"NICE's decision to delay patients access to innovative new treatments by three years is completely unacceptable and flies against the values and principles of a world-class NHS.
"If a medicine is deemed to be clinically and cost effective, it must be made available to patients. Delaying access by arbitrary periods will harm patient health and it will bind the hands of clinicians seeking to care for patients.
"AMRC is very worried about the impact on patients and the opportunity to build a strong life sciences sector in future. Government must urgently reconsider the introduction of this new budget impact test, otherwise it will be patients and their families that will pay the biggest price."